WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464771
CAS#: unknown
Description: VZMC013 is a potent chemical probe targeting MOR-CCR5 heterodimers and may serve as a pharmacological agent to inhibit opioid-exacerbated HIV-1 entry. VZMC013 possessed nanomolar level binding affinities for both the MOR and CCR5, inhibited CCL5-stimulated calcium mobilization, and remarkably improved anti-HIV-1BaL activity over previously reported bivalent ligands. VZMC013 inhibited viral infection in TZM-bl cells co-expressing CCR5 and MOR to a greater degree than cells expressing CCR5 alone. Furthermore, VZMC013 blocked human immunodeficiency virus (HIV)-1 entry in peripheral blood mononuclear cells (PBMC) cells in a concentration dependent manner and inhibited opioid-accelerated HIV-1 entry more effectively in phytohemagglutinin-stimulated PBMC cells than in the absence of opioids.
Hodoodo Cat#: H464771
Name: VZMC013
CAS#: unknown
Chemical Formula: C65H92F2N10O10
Exact Mass: 1,210.70
Molecular Weight: 1,211.508
Elemental Analysis: C, 64.44; H, 7.65; F, 3.14; N, 11.56; O, 13.21
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: VZMC013; VZMC 013; VZMC-013;
IUPAC/Chemical Name: N/A
InChi Key: RJZAGAMHLSCKAW-BNATVPKUSA-N
InChi Code: InChI=1S/C65H92F2N10O10/c1-41(2)61-74-73-53(77(61)48-34-46-16-17-47(35-48)76(46)31-23-49(43-11-7-6-8-12-43)72-62(83)44-19-24-63(66,67)25-20-44)22-30-70-56(81)39-85-37-54(79)68-28-9-4-3-5-10-29-69-55(80)38-86-40-57(82)71-50-21-26-65(84)52-33-45-15-18-51(78)59-58(45)64(65,60(50)87-59)27-32-75(52)36-42-13-14-42/h6-8,11-12,15,18,41-42,44,46-50,52,60,78,84H,3-5,9-10,13-14,16-17,19-40H2,1-2H3,(H,68,79)(H,69,80)(H,70,81)(H,71,82)(H,72,83)/t46-,47+,48-,49-,50+,52+,60?,64-,65+/m0/s1
SMILES Code: O=C(COCC(NCCCCCCCNC(COCC(NCCC1=NN=C(C(C)C)N1[C@H]2C[C@H]3N(CC[C@H](NC(C4CCC(F)(F)CC4)=O)C5=CC=CC=C5)[C@H](CC3)C2)=O)=O)=O)N[C@H](CC6)C7[C@]([C@]6(O)[C@H]8C9)(CCN8CC%10CC%10)C%11=C9C=CC(O)=C%11O7
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 1,211.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Huang B, Wang H, Zheng Y, Li M, Kang G, Barreto-de-Souza V, Nassehi N, Knapp PE, Selley DE, Hauser KF, Zhang Y. Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. J Med Chem. 2021 Jun 10;64(11):7702-7723. doi: 10.1021/acs.jmedchem.1c00408. Epub 2021 May 23. PMID: 34027668.